Physician profile
Ted P Kemp
NPI 1821094574
$1,048.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $414 · 2021: $306.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $182.88 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.50 | 2020-2021 | |
| Glaxosmithkline, LLC. | $148.68 | 2019-2021 | |
| Pfizer INC. | $126.81 | 2019-2021 | |
| Lilly USA, LLC | $119.75 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $97.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.92 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $27.80 | 2019 | |
| Allergan, INC. | $26.12 | 2020 | |
| Abbvie INC. | $24.11 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.17 | 2020 | |
| Eisai INC. | $18.49 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.58 | 2019 | |
| Sanofi Pasteur INC. | $11.67 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.